France-based Neovacs has entered a licensing agreement with South Korea’s Chong Kun Dang (CKD) Pharmaceutical Corp. to market IFNα-Kinoïd for lupus and dermatomyositis in South Korea. In South Korea lupus is considered an orphan disease, with an estimated market just below 20,000 patients. CKD says it plans to start the registration process with the South Korean health authority by the end of 2017, following successful completion of an ongoing Phase IIb trial, which includes five investigatio...